Jiangsu CoWin Biotech Co., Ltd. (SHA:688426)

Jiangsu CoWin Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	137.46	255.47	348.34	1,032	127.83	38.84
Short-Term Investments	-	60.54	90.01	-	-	-
Trading Asset Securities	512.64	417.04	545.28	402.59	233.42	303.17
Cash & Short-Term Investments	650.1	733.05	983.64	1,434	361.25	342.01
Cash Growth	-23.57%	-25.48%	-31.41%	297.00%	5.63%	3525.14%
Accounts Receivable	52.62	43.28	58.96	129.64	36.56	25.94
Other Receivables	3.13	-	-	0.31	-	1.1
Receivables	55.76	43.28	58.96	129.95	36.56	27.04
Inventory	53.83	45.87	32.04	52.53	32.62	24.22
Other Current Assets	73.04	11.21	10.04	10.05	7.72	4.07
Total Current Assets	832.72	833.4	1,085	1,627	438.16	397.34
Property, Plant & Equipment	371.75	381.13	394.39	246.43	159.44	30.19
Long-Term Investments	288.43	296.81	256.71	-	-	-
Goodwill	1.08	1.08	-	4.27	-	-
Other Intangible Assets	49.24	49.97	29.77	29.35	30.15	0.65
Long-Term Deferred Tax Assets	35.57	32.5	29.83	17.11	4	5.67
Long-Term Deferred Charges	19.98	20.73	24.8	11.36	13.82	9.3
Other Long-Term Assets	4.82	2.52	2.04	20.06	3.2	2.49
Total Assets	1,604	1,618	1,822	1,955	648.77	445.64
Accounts Payable	36.38	31.86	47.53	44.07	10.55	5.41
Accrued Expenses	-	18.51	16.69	21.69	22.12	8.86
Short-Term Debt	10.01	6.01	-	-	-	-
Current Portion of Leases	11.44	12.12	13.65	9.05	5.67	-
Current Income Taxes Payable	0.35	-	-	9.56	8.21	1.97
Current Unearned Revenue	5.68	9.63	4.48	5.75	10.28	7.49
Other Current Liabilities	9.12	5.87	2.51	3.03	3.58	2.14
Total Current Liabilities	72.98	84	84.86	93.15	60.41	25.86
Long-Term Leases	7.41	9.71	19.31	31.72	34.33	-
Long-Term Unearned Revenue	54.04	30.25	30.11	29.58	5.67	5.52
Long-Term Deferred Tax Liabilities	7.92	7.75	8.32	9.1	0.06	0.24
Other Long-Term Liabilities	0.1	0.09	0.06	0.05	0.04	0.03
Total Liabilities	142.45	131.79	142.67	163.6	100.51	31.65
Common Stock	112.49	112.49	112.23	93.52	69.87	69.87
Additional Paid-In Capital	1,395	1,394	1,391	1,393	344.45	336.02
Retained Earnings	-19.87	2.87	160.08	293.13	133.87	8.02
Treasury Stock	-47.67	-43.66	-	-	-	-
Comprehensive Income & Other	0.33	0.33	0.3	0.27	0.07	0.09
Total Common Equity	1,441	1,466	1,664	1,780	548.26	414
Minority Interest	20.43	20.56	15.88	11.31	-	-
Shareholders' Equity	1,461	1,486	1,680	1,792	548.26	414
Total Liabilities & Equity	1,604	1,618	1,822	1,955	648.77	445.64
Total Debt	28.85	27.84	32.95	40.77	39.99	-
Net Cash (Debt)	621.25	705.21	950.68	1,393	321.25	342.01
Net Cash Growth	-24.21%	-25.82%	-31.77%	333.73%	-6.07%	3525.14%
Net Cash Per Share	5.61	6.32	8.45	15.00	3.81	4.89
Filing Date Shares Outstanding	109.93	110.11	112.49	112.23	83.85	83.85
Total Common Shares Outstanding	109.93	110.11	112.23	112.23	83.85	83.85
Working Capital	759.74	749.41	999.82	1,534	377.75	371.48
Book Value Per Share	13.11	13.31	14.82	15.86	6.54	4.94
Tangible Book Value	1,390	1,415	1,634	1,747	518.11	413.35
Tangible Book Value Per Share	12.65	12.85	14.56	15.56	6.18	4.93
Buildings	-	235.28	234.89	0.66	0.66	0.66
Machinery	-	207.97	188.41	133.11	75.91	40.96
Construction In Progress	-	0.37	-	110.9	64.81	0.61

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.